Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02428608 | Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 | PHASE2 | COMPLETED | 570 | — | — | May 1, 2015 | Nov 1, 2016 | Apr 24, 2019 | 1 | United States |
The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365.
| Arm | Type | Description |
|---|---|---|
| Botulinum toxin, Tyoe A | EXPERIMENTAL | DWP-450 (Botulinum toxin, Type A) |
| Name | Type | Description |
|---|---|---|
| DWP-450 (Botulinum purified neurotoxin, Type A) | BIOLOGICAL | Botulinum toxin, Type A |
Inclusion Criteria: * Subjects must be an adult 18 years of age and over * Subject is able to provide informed consent and comply with study instructions * Subject has moderate-to-severe glabellar lines on maximum frown as assessed by the investigator and subject using the GLS * Subject is willing ...